Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
- 25 February 2021
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 397 (10279), 1057-1058
- https://doi.org/10.1016/s0140-6736(21)00501-8
Abstract
No abstract availableKeywords
Funding Information
- Barts Charity
- Wellcome Trust
This publication has 4 references indexed in Scilit:
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infectionScience Immunology, 2020
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesThe New England Journal of Medicine, 2020
- COVID-19: PCR screening of asymptomatic health-care workers at London hospitalThe Lancet, 2020